Disease activity level, remission and response in established rheumatoid arthritis: Performance of various criteria sets in an observational cohort, treated with anti-TNF agents

被引:31
|
作者
Gulfe, Anders [1 ]
Aletaha, Daniel [2 ]
Saxne, Tore [1 ]
Geborek, Pierre [1 ]
机构
[1] Univ Lund Hosp, Dept Rheumatol, S-22185 Lund, Sweden
[2] Med Univ Vienna, Vienna, Austria
来源
BMC MUSCULOSKELETAL DISORDERS | 2009年 / 10卷
关键词
COLLEGE-OF-RHEUMATOLOGY; CLINICAL-PRACTICE; ACTIVITY INDEX; VALIDATION; PREDICTORS; REGISTER; THERAPY;
D O I
10.1186/1471-2474-10-41
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background: Most composite indices of disease activity and response criteria in RA have been validated and compared in clinical trials rather than routine care. We therefore wanted to compare the performance of the DAS28, SDAI and CDAI activity indices, their activity states, their response criteria, and also compare with the ACR response criteria in an observational clinical setting. Methods: Agreement between the criteria sets was investigated using kappa statistics in a non-randomized cohort of 1789 RA patients from southern Sweden, starting their first course of anti-TNF-treatment. Mean disease duration was 12 years. Completer analysis was used. Results: Agreement between high, moderate and low activity states was moderate or substantial, with. = 0.5 or better for all criteria. Agreement between SDAI and CDAI disease states was > 90% in these categories with kappa > 0.8. DAS28 original and modified cut point remission had good agreement (kappa = 0.91). Agreement between responses was substantial at the overall/ACR20 level (about 95%, kappa = 0.7 or better) for all criteria. By contrast, agreement was poor between moderate and high level responses. Conclusion: Disease activity states according to the various indices perform similarly and show substantial agreement at all levels except remission. Agreement between SDAI and CDAI states is excellent. Response criteria, applied at the individual patient level, are hard to interpret and show poor agreement, except at the lowest level of response. Thus, they should not be applied uncritically in clinical practice.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] COMPARISON OF ACR/EULAR AND DAS28 REMISSION CRITERIA IN A COHORT OF TNF INHIBITOR TREATED RHEUMATOID ARTHRITIS PATIENTS
    Balogh, E.
    Dias, J. M.
    Mullan, R.
    Harty, L. C.
    Gallagher, P.
    Molloy, M.
    O'Flynn, E.
    O'Kelly, A.
    O'Neill, M.
    Moore, L.
    Murray, M.
    FitzGerald, O.
    Fearon, U.
    Veale, D. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 213 - 213
  • [42] Response to pneumococcal vaccine in rheumatoid arthritis patients with an inadequate response to anti-TNF therapy treated with abatacept in the arrive trial
    Schiff, M.
    Kaell, A.
    Tay, L.
    Vratsanos, G.
    Bahrt, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 437 - 437
  • [43] Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs
    Perrotta, Fabio Massimo
    Marchesoni, Antonio
    Lubrano, Ennio
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (02) : 350 - 355
  • [44] Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis
    Iwaszko, Milena
    Swierkot, Jerzy
    Kolossa, Katarzyna
    Jeka, Slawomir
    Wiland, Piotr
    Bogunia-Kubik, Katarzyna
    GENES, 2018, 9 (02)
  • [45] Autoimmune Hepatitis Triggered by Adalimumab and Allergic Reactions after Various Anti-TNFα Therapy Agents in a Patient with Rheumatoid Arthritis
    Petrikova, Jana
    Jarcuska, Peter
    Svajdler, Marian
    Pella, Daniel
    Macejova, Zelmira
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2015, 17 (04): : 256 - 258
  • [46] The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
    de Punder, Yvonne M. R.
    Fransen, Jaap
    Kievit, Wietske
    Houtman, Pieternella M.
    Visser, Henk
    van de Laar, Mart A. F. J.
    van Riel, Piet L. C. M.
    RHEUMATOLOGY, 2012, 51 (09) : 1610 - 1617
  • [47] SAFETY AND EFFICACY OF CERTOLIZUMAB COMPARED WITH OTHER ANTI-TNF AGENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED AT BUCKS HEALTHCARE TRUST
    Selvan, Shilpa
    Magliano, Malgosia
    Hall, Jackie
    RHEUMATOLOGY, 2015, 54 : 102 - 102
  • [48] IMPACT OF ANTI-TNF TREATMENT IN DISEASE ACTIVITY AND FUNCTIONAL CAPACITY OF PATIENTS WITH RHEUMATOID ARTHRITIS IN MATURIN, VENEZUELA
    Granados, Y.
    Berbin, S.
    Figuera, Y.
    Gonzalez, R.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2010, 16 (03) : S38 - S38
  • [50] Physical function (haq) response in clinical practice in ra patients treated with anti-TNF agents and after switching to a second or a third anti-TNF agent: Results of an observational, prospective, cohort study in Spain.
    Navarro, Federico
    Gomez Reino, Juan
    Marsal, Sara
    Ruiz, Ma Dolores
    Hernandez-Cruz, Blanca
    Perez Pampin, Eva
    Cefferino, Cesar
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S383 - S384